Hydroxyarenes

Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference

Retrieved on:

Tuesday, May 11, 2021

Branches of biology, Neuroscience, Neurotransmitters, TAAR1 agonists, Psychedelic drugs, Hydroxyarenes, Serotonin, Serotonergic, Psilocybin

b'The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.\nBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.

Key Points:

b'The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.\nBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs.
Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.\n'

CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep Gummies

Retrieved on:

Tuesday, May 11, 2021

Amino acids, Branches of biology, Amines, Hydroxyarenes, Dietary Supplements, Neurotransmitters, Anxiolytics, Theanine, 5-Hydroxytryptophan, Serotonin, Tryptophan, HTP

Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood.

Key Points:

Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood.
L-Theanine is an amino acid found in green tea that has been extensively researched for stress management.
PlusCBD\xe2\x84\xa2 Calm and Sleep gummies contain no artificial flavoring or sweeteners, making them an attractive option for those looking to support their stress response and sleep cycle without artificial additives.
\xe2\x80\x9cOur Calm and Sleep gummies underscore the Company\xe2\x80\x99s ongoing commitment to advancing the CBD industry through science-backed formulations.\xe2\x80\x9d\nCV, or Curriculum Vitae, is Latin for \xe2\x80\x9ccourse of life\xe2\x80\x9d, and science is the pursuit of truth.

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021

Retrieved on:

Monday, April 19, 2021

Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Ebola, Chemical compounds, COVID-19, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, XC2, Antiviral drug, Infection

By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Key Points:

By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan\xc2\xae / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
Led by a proven management team, Appili is at the epicenter of the global fight against infection.
For more information, visit www.AppiliTherapeutics.com .\nBloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.

Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today

Retrieved on:

Wednesday, February 24, 2021

Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Chemical compounds, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Infection, Biocom Global, Appili Therapeutics

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.

Key Points:

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

Retrieved on:

Thursday, January 28, 2021

PRESECO is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.

Key Points:

PRESECO is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.
Our PRESECO study is designed to answer the critical question, does favipiravir work for COVID-19 patients early in the outpatient setting?
Appili plans to prioritize its resources to accelerate recruitment and data analysis for the PRESECO study.
As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral favipiravir for the worldwide treatment and prevention of COVID-19.

Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Interim Order

Retrieved on:

Tuesday, December 22, 2020

If approved, we look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.

Key Points:

If approved, we look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.
Our role remains to design rigorous trials to obtain the data that identify COVID-19 patients that may benefit from REEQONUS.
Our outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation.
According to Health Canada, REEQONUS (favipiravir) Tablets are the first oral solid dosage form submitted under the Interim Order.

Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19

Retrieved on:

Friday, October 30, 2020

The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.

Key Points:

The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.
The clinical development strategy will focus on evaluating Avigan tablets for early treatment and post-exposure prophylaxis in the community setting.
In collaboration with its partners, Appili will design and oversee Phase 3 clinical trials to support regulatory submissions worldwide.
In addition, the Company is also testing FUJIFILM Toyama Chemical Inc.s drug Avigan for the potential treatment and prevention of COVID-19.

Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA

Retrieved on:

Friday, September 11, 2020

FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Health, Chemistry, Physical sciences, Ebola, Organofluorides, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Coronavirus disease, Placebo-controlled study, COVID-19 drug repurposing research

Appilis study is designed to be a randomized, double-blind placebo-controlled, multi-center Phase 3 trial investigating the safety and efficacy of favipiravir in the early treatment outpatient setting for adult COVID-19 infections with mild to moderate symptoms.

Key Points:

Appilis study is designed to be a randomized, double-blind placebo-controlled, multi-center Phase 3 trial investigating the safety and efficacy of favipiravir in the early treatment outpatient setting for adult COVID-19 infections with mild to moderate symptoms.
Appili plans to recruit 826 eligible participants, who are recently diagnosed as COVID-19 positive with mild to moderate symptoms, across multiple clinical trial sites in the U.S.
In a sub study, researchers intend to further examine 136 trial participants to evaluate favipiravirs effect on viral shedding.
In addition, the Company is also testing FUJIFILM Toyama Chemical Inc.s drug favipiravir for the prevention of COVID-19 as a potential prophylaxis treatment.

Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds

Retrieved on:

Monday, August 31, 2020

Psychoactive drugs, Entheogens, Drugs, Mycotoxins, Organic compounds, Hydroxyarenes, Psychedelic drugs, Hallucinations, Serotonin, Psilocybin, Psilocin, Hallucinogen

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.

Key Points:

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.
Mindset has conducted several pharmacological tests on its proprietary synthesized compounds, including a gold-standard functional assay to determine its molecules' functional activity at the human 5HT-2A receptor and other serotonin subtypes, benchmarking these compounds against psilocin, a major active metabolite of psilocybin.
Mindset is pleased to report that these synthesized compounds are acting just as strongly on the 5HT-2A receptor as psilocin, with clear structure-affinity relationship (SAR), and with certain compounds demonstrating a several-fold increase in efficacy and potency compared to psilocin.
Mindset CEO James Lanthier comments, "Next-generation psychedelic compounds that are optimized for their pharmacological profile will be essential to assisting the greatest possible number of patients suffering from neuropsychiatric indications.

The Lancet: Excellent Efficacy of Hisun's Favipiravir Against COVID-19 in Turkey

Retrieved on:

Wednesday, August 26, 2020

Chemistry, Physical sciences, Ebola, Chemical compounds, Favipiravir, Hydroxyarenes, Isomerism, Organofluorides, Pyrazines, Management of COVID-19, Fahrettin Koca

TAIZHOU, China, Aug. 26, 2020 /PRNewswire/ -- Recently, Preprints with The Lancet has published a preliminary study report on Turkey's using Favipiravir produced by Hisun to treat COVID-19.

Key Points:

TAIZHOU, China, Aug. 26, 2020 /PRNewswire/ -- Recently, Preprints with The Lancet has published a preliminary study report on Turkey's using Favipiravir produced by Hisun to treat COVID-19.
The Turkish Government has taken a series of preventive measures since the outbreak of COVID-19 in early January.
Later on March 25, it incorporated Favipiravir into the COVID-19 treatment scheme and sent one million Favipiravir tablets purchased from Hisun to hospitals all over the country for the free treatment of COVID-19 patients.
Turkey's Health Minister Fahrettin Koca said, with the early use of Favipiravir in Turkey, the pneumonia rate sees a gradual decline and that in Ankara, the capital of Turkey, has dropped from 12.1% to 5.61% ( https://anadoludabugun.com.tr/turkiye/saglik-bakani-koca-evde-tedavide-y... ).